ALHEMO 150 MG/1,5 ML SOLUCION INYECTABLE EN PLUMA PRECARGADA

USDailyMed:Concizumab AU:D B02BX10(WHO) AU:S4(Prescription only)CA:℞-only/Schedule DUS:℞-onlyEU:Rx-only 1312299-39-0 DB12820 68603V9EAF D11847 Concizumab, sold under the brand nameAlhemo, is amonoclonal antibodyused for the treatment ofhemophilia Aandhemophilia B.It is an anti-tissue factor pathway inhibitor. The most common adverse reactions include injection site reactions and hives (urticaria).Concizumab can cause thromboembolic events, hypersensitivity, and increased laboratory values of fibrin D dimer and prothrombin fragment 1+2. Concizumab was approved for medical use in Canada in March 2023,in Australia in July 2023,in the European Union in December 2024,and the United States in December 2024.